Harbin Medisan Pharmaceutical Co Ltd (002900) — Capital Reinvestment Ratio

Latest as of March 2025: 0.79x

Harbin Medisan Pharmaceutical Co Ltd (002900) has a Capital Reinvestment Ratio of 0.79x as of March 2025, meaning it reinvests 1% of its operating cash flow (CN¥86.31 Million) in capital expenditures (CN¥68.40 Million). See 002900 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.

Capital Reinvestment Ratio

0.79x
Capex / Operating Cash Flow

Operating Cash Flow

CN¥86.31 Million
CNY

Capital Expenditures

CN¥68.40 Million
CNY

Data as of

Mar 2025
Most recent filing

Harbin Medisan Pharmaceutical Co Ltd Capital Reinvestment Ratio (2012–2024)

This chart tracks Harbin Medisan Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 11 annual periods.

Annual Capital Reinvestment Ratio for Harbin Medisan Pharmaceutical Co Ltd (2012–2024)

Year-by-year Capital Reinvestment Ratio for Harbin Medisan Pharmaceutical Co Ltd from 2012 to 2024. For live market cap and broader valuation context, see market value of Harbin Medisan Pharmaceutical Co Ltd.

Year Reinvestment Ratio Operating CF (CNY) Capital Expenditures YoY Change
2024 11.28x CN¥30.69 Million CN¥346.21 Million ▲ +34.4%
2023 8.39x CN¥35.69 Million CN¥299.58 Million ▲ +1260.6%
2022 0.62x CN¥144.64 Million CN¥89.22 Million ▼ -0.6%
2019 0.62x CN¥320.14 Million CN¥198.63 Million ▲ +131.4%
2018 0.27x CN¥292.46 Million CN¥78.41 Million ▼ -42.9%
2017 0.47x CN¥223.46 Million CN¥104.93 Million ▲ +15.6%
2016 0.41x CN¥231.18 Million CN¥93.88 Million ▼ -42.4%
2015 0.71x CN¥200.85 Million CN¥141.72 Million ▼ -43.7%
2014 1.25x CN¥116.31 Million CN¥145.81 Million ▲ +35.9%
2013 0.92x CN¥167.10 Million CN¥154.13 Million ▲ +24.9%
2012 0.74x CN¥123.22 Million CN¥91.01 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow